FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895526782> ?p ?o ?g. }

• W2895526782 endingPage "420" @default.
• W2895526782 startingPage "410" @default.
• W2895526782 abstract "Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC. Prospectively scored maintenance clinical (26.5 weeks; interquartile range [IQR], 16.3–37.0 weeks) and endoscopic (23.5 weeks; IQR, 16.8–35.6 weeks) outcomes were compared with serum vedolizumab concentrations, antivedolizumab antibodies, and serum biomarkers at baseline and weeks 2, 6, 14, and 26. A linear mixed-effects model compared biomarker trajectories over time between clinical and endoscopic remitters and nonremitters. Thirty-two patients were included. Soluble (s)–tumor necrosis factor (TNF)–α, s-α4β7, s-mucosal addressin cell adhesion molecule (s-MAdCAM-1), and s-amyloid A (s-AA) significantly changed with treatment. A linear mixed-effects model demonstrated that s-α4β7 (P = 0.044) increased and s-MAdCAM-1 (P = 0.006) and s-vascular cell adhesion molecule-1 (s-VCAM-1, P = 0.001) decreased more rapidly in patients achieving clinical remission in maintenance. S-MAdCAM-1 (P = 0.005), s-intracellular adhesion molecule-1 (ICAM-1; P = 0.014), s-VCAM-1 (P < 0.001), and s-TNF (P = 0.052) decreased more rapidly in endoscopic remitters. In clinical remitters, higher week 14 (20.3 ng/mL vs 6.0 ng/mL; P = 0.013) and week 26 (14.1 ng/mL vs 8.6 ng/mL; P = 0.05) s-α4β7 were observed. In endoscopic remitters, week 2 (6.7 pg/mL vs 17.8 pg/mL; P = 0.038) and week 6 (3.9 pg/mL vs 15.6 pg/mL; P = 0.005) s-TNF and week 14 s-VCAM (589.1 ng/mL vs 746.0 ng/mL; P = 0.05) were lower. Serum biomarkers were associated with outcomes in vedolizumab-treated UC patients. s-α4β7 increased, whereas s-MAdCAM-1, s-VCAM-1, s-ICAM-1, and s-TNF decreased more rapidly in remitters. At individual time points, induction s-TNF and maintenance s-VCAM-1 concentrations were lower, whereas maintenance s-α4β7 concentrations were higher in remitters." @default.
• W2895526782 created "2018-10-12" @default.
• W2895526782 creator A5001687106 @default.
• W2895526782 creator A5009375239 @default.
• W2895526782 creator A5012998783 @default.
• W2895526782 creator A5016530589 @default.
• W2895526782 creator A5021685813 @default.
• W2895526782 creator A5022111230 @default.
• W2895526782 creator A5025171267 @default.
• W2895526782 creator A5028280882 @default.
• W2895526782 creator A5032150391 @default.
• W2895526782 creator A5035847062 @default.
• W2895526782 creator A5044792021 @default.
• W2895526782 creator A5050920863 @default.
• W2895526782 creator A5052596220 @default.
• W2895526782 creator A5056035336 @default.
• W2895526782 creator A5088982093 @default.
• W2895526782 date "2018-10-05" @default.
• W2895526782 modified "2023-10-06" @default.
• W2895526782 title "Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis" @default.
• W2895526782 cites W1551592047 @default.
• W2895526782 cites W1575253744 @default.
• W2895526782 cites W1937095587 @default.
• W2895526782 cites W1951724000 @default.
• W2895526782 cites W1967312170 @default.
• W2895526782 cites W1981526780 @default.
• W2895526782 cites W1982947309 @default.
• W2895526782 cites W1993598111 @default.
• W2895526782 cites W1998231725 @default.
• W2895526782 cites W2000069945 @default.
• W2895526782 cites W2011837830 @default.
• W2895526782 cites W2023078169 @default.
• W2895526782 cites W2023497290 @default.
• W2895526782 cites W2027397742 @default.
• W2895526782 cites W2030262883 @default.
• W2895526782 cites W2077531651 @default.
• W2895526782 cites W2102116540 @default.
• W2895526782 cites W2142678320 @default.
• W2895526782 cites W2152910353 @default.
• W2895526782 cites W2155989401 @default.
• W2895526782 cites W2160619682 @default.
• W2895526782 cites W2162805528 @default.
• W2895526782 cites W2169051283 @default.
• W2895526782 cites W2188248802 @default.
• W2895526782 cites W2274605499 @default.
• W2895526782 cites W2318308421 @default.
• W2895526782 cites W2329755771 @default.
• W2895526782 cites W2460337359 @default.
• W2895526782 cites W2556146932 @default.
• W2895526782 cites W2559806380 @default.
• W2895526782 cites W2587354427 @default.
• W2895526782 cites W2589422996 @default.
• W2895526782 cites W2606096564 @default.
• W2895526782 cites W2616235887 @default.
• W2895526782 cites W2728540238 @default.
• W2895526782 cites W2773289068 @default.
• W2895526782 cites W2790663920 @default.
• W2895526782 cites W2792406291 @default.
• W2895526782 cites W2794186149 @default.
• W2895526782 cites W2804630856 @default.
• W2895526782 cites W2806579687 @default.
• W2895526782 cites W4296224660 @default.
• W2895526782 doi "https://doi.org/10.1093/ibd/izy307" @default.
• W2895526782 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6327228" @default.
• W2895526782 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30295781" @default.
• W2895526782 hasPublicationYear "2018" @default.
• W2895526782 type Work @default.
• W2895526782 sameAs 2895526782 @default.
• W2895526782 citedByCount "24" @default.
• W2895526782 countsByYear W28955267822019 @default.
• W2895526782 countsByYear W28955267822020 @default.
• W2895526782 countsByYear W28955267822021 @default.
• W2895526782 countsByYear W28955267822022 @default.
• W2895526782 countsByYear W28955267822023 @default.
• W2895526782 crossrefType "journal-article" @default.
• W2895526782 hasAuthorship W2895526782A5001687106 @default.
• W2895526782 hasAuthorship W2895526782A5009375239 @default.
• W2895526782 hasAuthorship W2895526782A5012998783 @default.
• W2895526782 hasAuthorship W2895526782A5016530589 @default.
• W2895526782 hasAuthorship W2895526782A5021685813 @default.
• W2895526782 hasAuthorship W2895526782A5022111230 @default.
• W2895526782 hasAuthorship W2895526782A5025171267 @default.
• W2895526782 hasAuthorship W2895526782A5028280882 @default.
• W2895526782 hasAuthorship W2895526782A5032150391 @default.
• W2895526782 hasAuthorship W2895526782A5035847062 @default.
• W2895526782 hasAuthorship W2895526782A5044792021 @default.
• W2895526782 hasAuthorship W2895526782A5050920863 @default.
• W2895526782 hasAuthorship W2895526782A5052596220 @default.
• W2895526782 hasAuthorship W2895526782A5056035336 @default.
• W2895526782 hasAuthorship W2895526782A5088982093 @default.
• W2895526782 hasBestOaLocation W28955267822 @default.
• W2895526782 hasConcept C119060515 @default.
• W2895526782 hasConcept C126322002 @default.
• W2895526782 hasConcept C170493617 @default.
• W2895526782 hasConcept C185592680 @default.
• W2895526782 hasConcept C195687474 @default.
• W2895526782 hasConcept C2776207728 @default.
• W2895526782 hasConcept C2779134260 @default.

• next